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Abstract. Background: We sought a diagnostic tool using
perioperative variables that might predict post-hepatectomy liver
failure (PHLF). Patients and Methods: In 68 patients
undergoing major hepatectomy, data on inflammatory markers
and coagulation factors were prospectively collected and were
compared between patients with International Study Group of
Liver Surgery definition grade B/C PHLF (LF group) and those
without LF (non-LF group). Results: Preoperatively, the LF
group (n=9; 13.2%) had a lower platelet count and a
disintegrin-like and metalloproteinase with thrombospondin type
1 motifs 13 (ADAMTS13) activity and a higher prothrombin
time-International Normalized Ratio (PT-INR) than the non-LF
group. On postoperative day 1, the LF group had significantly
higher serum interleukin 6 (IL6), C-C motif chemokine ligand 2
(CCL2), and IL10 levels than the non-LF group. The logistic
regression model that included preoperative PT-INR and CCL2
on postoperative day 1 predicted grade B/C PHLF with 100%
sensitivity and 89.8% specificity. Conclusion: Our findings
suggest that the combination of preoperative PT-INR and CCL2
on postoperative day 1 can predict PHLF earlier and precisely
after major hepatectomy. 
Although hepatectomy can currently be performed quite
safely due to remarkable refinements in surgical techniques,
perioperative management, and surgeon experience, the
morbidity and mortality rates after major hepatectomy
remain 30-45% and 3-5%, respectively (1-5). Post-
hepatectomy liver failure (PHLF) particularly easily leads to
mortality. Therefore, various models using preoperative
variables have been devised to predict PHLF (6-9). However,
PHLF cannot be completely prevented using these existing
models. 
The International Study Group of Liver Surgery (ISGLS)
proposed a definition of PHLF in 2011 (10) that had reliable
prognostic value, as ISGLS grade B/C PHLF often led to
severe morbidity or mortality (11). However, the diagnosis
of PHLF based on the ISGLS definition as well as other
established criteria, such as the 50-50 criteria (12) or
PeakBili>7 criteria (13), requires about 5 days to have elapsed
after hepatectomy, by which point it may be too late to
intervene (10-13). Even though treatments of PHLF itself
have not been established, the outcomes of hepatectomy
might be improved by prevention or earlier intervention if a
diagnostic tool for predicting PHLF much earlier than
postoperative day (POD) 5 can be constructed.
LF is considered multifactorial and often associated with
sepsis (14-16). Immediate responses of various inflammatory
and coagulation markers, such as interleukin-6 (IL6) or
plasminogen activator inhibitor-1 (PAI1), have been
reportedly involved in the development of severe sepsis and
significantly correlated with the treatment outcomes (17-21).
Furthermore, such immediate responses have been observed
in the early phase after hepatectomy and are significantly
associated with the development of PHLF (22-24).
We considered that such immediate responses after
hepatectomy have a significant role in developing PHLF, as
well as predictive value for PHLF, especially in combination
with preoperative variables. In the present study, we
investigated the chronological changes in perioperative
variables, including inflammatory cytokines, coagulation, and
fibrinolytic factors, in order to construct a diagnostic model
for predicting PHLF precisely and much earlier than POD5.
Patients and Methods
The perioperative variables of 68 patients undergoing major
hepatectomy, including right or left hemi-hepatectomy and right or
left trisectionectomy, between October 2013 and October 2015 at
the Yokohama City University Hospital were investigated. The
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patient characteristics are summarized in Table I. Twenty-five
patients (37%) underwent pre-hepatectomy chemotherapy. Twenty-
seven patients (40%) had biliary reconstruction. Twenty-four
patients (35%) had concomitant vascular resection and
reconstruction. Five patients (7%) underwent concomitant
pancreaticoduodenectomy. Written-informed consent, as approved
by the Human Research Review Committee of Yokohama City
University Hospital (no. 131107018), was obtained from all patients
prior to their enrollment in our study.
Preoperative management. We judged hepatectomy to have been
performed with acceptable safety when the following criteria were
fulfilled: Indocyanine green kinetics value for the liver remnant
(rICGK) (9) of more than 0.05 and more than 300 ml of functional
liver remnant. The liver and tumor volume were measured by
computed tomographic volumetry (25). Portal vein embolization
(PVE) was performed before right hepatectomy and before right or
left trisectionectomy.
Blood sampling and measurement of pro-/anti-inflammatory
markers and coagulation/fibrinolysis factors. Peripheral blood
samples were obtained before the operation and on POD1, 3, and 5.
In addition to usual laboratory tests in daily clinical practice, the
following pro- and anti-inflammatory cytokines, coagulation, and
fibrinolytic factors were measured at each time point: IL1β, C-C
motif chemokine ligand 2 (CCL2), IL6, activities of a disintegrin-
like and metalloproteinase with thrombospondin type 1 motifs 13
(ADAMTS13), and von Willebrand factor (vWF). 
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Table I. Clinical characteristics of patients in the groups with post-hepatectomy liver failure (LF) and without (non-LF).
Variable Total n=68 LF group n=9 Non-LF group n=59 p-Value
Age, years Mean±SD 62±16 66±10 61±16 0.751
Gender, n (%) Male 43 (63%) 6 (67%) 37 (63%) 0.819
Disease, n (%) Cholangiocarcinoma 32 (47%) 5 (56%) 27 (46%)
Hepatocellular carcinoma 11 (16%) 1 (11%) 10 (17%)
Liver metastasis 13 (19%) 2 (22%) 11 (19%) 0.801
LDLT donor 5 (7%) 1 (11%) 4 (7%)
Other 7 (10%) 0 7 (12%)
Liver function ICG-R15, % 12.9±5.9 16.5±7.5 12.3±5.5 0.128
Serum total bilirubin, mg/dl 0.6±0.3 0.9±0.67 0.61±0.21 0.151
Serum albumin, g/dl 3.3±0.5 3.0±0.5 3.4±0.4 0.030
PT-INR 1.1±0.1 1.21±0.15 1.08±0.08 0.009
Preoperative cholangitis, n (%) Yes 18 (26%) 3 (33%) 15 (25%) 0.616
Preoperative treatment, n (%) Chemotherapy 25 (37%) 5 (56%) 20 (24%) 0.209
Portal vein embolization 33 (49%) 5 (56%) 28 (48%) 0.651
Preoperative biliary drainage 23 (34%) 4 (44%) 19 (32%) 0.470
Anticoagulant therapy 9 (13%) 1 (11%) 8 (14%) 0.840
Preoperative planning, mean±SD Resection volume, ml 510±239 615±289 494±229 0.222
Resection rate, % 44±15 53±13 42±15 0.054
Remnant liver volume, ml 634±238 502±106 654±247 0.054
Predictive score 32±22 49±13 30±22 0.012
rICGK 0.08±0.03 0.06±0.01 0.08±0.03 <0.001
Procedure, n (%) Right hemi-hepatectomy 31 (46%) 4 (44%) 27 (46%) 0.941
Left hemi-hepatectomy 27 (40%) 2 (22%) 25 (42%) 0.250
Right trisectionectomies 4 (6%) 1 (11%) 3 (5%) 0.474
Left trisectionectomies 6 (9%) 2 (22%) 4 (7%) 0.128
Additional procedure, n (%) Pancreatico-duodenectomy 5 (7%) 0 5 (9%) 0.364
Biliary tract reconstruction 27 (40%) 5 (56%) 22 (37%) 0.297
Blood vessel reconstruction 24 (35%) 6 (67%) 18 (31%) 0.034
Intraoperative factors Operative time, min 656±230 859±362 625±188 0.078
Bleeding, ml 1407±1020 3321±3404 1115±702 0.189
RCC transfusion, ml 329±748 1307±1615 180±340 <0.001
Morbidity, n (%) Total 19 (28%) 5 (56%) 14 (24%) 0.047
Infection 11 (16%) 3 (33%) 8 (14%) 0.310
Bleeding 6 (9%) 2 (22%) 4 (7%) 0.128
Thrombosis 0 0 0 0.694
Other 4 (6%) 0 4 (7%) 0.421
Length of hospital stay, days Mean±SD 21±20 47±43 17±3 0.025
In-hospital mortality Frequency, % 3 (4%) 3 (33%) 0 <0.001
LDLT: Living donor liver transplantation; ICG-R15; ICG retention rate at 15 minutes; PT-INR: prothrombin time-International Normalized Ratio;
rICGK: Indocyanine green kinetics value for the liver remnant [=ICG K (ICG plasma disappearance rate)×remnant liver rate]; RCC: red-blood cell
concentrate. Bold values show significance.
The serum levels of IL6 were quantified using a two-step
sandwich chemiluminescence enzyme immunoassay method. The
serum levels of IL1β (Quantikine HS human IL-1β Immunoassay;
R&D Systems, Minneapolis, MN, USA) and CCL2 (Quantikine
Human MCP-1 Immunoassay; R&D Systems) were quantified using
enzyme-linked immunosorbent assays. ADAMTS13 activity was
measured using a chromogenic substrate (26). The level of vWF
activity was measured using the fixed-platelet aggregation method.
The prothrombin time international normalized ratio (PT-INR) was
measured using a method designed by Quick (HemosIL
RecombiPlasTin; Japan, Tokyo, Japan). Plasma fibrinogen levels
were measured using the Clauss method (HemosIL Fib, Japan).
Plasma fibrin and fibrinogen degradation products-E (FDP-E) levels
were measured using a latex photometric immunoassay (LPIA FDP-
E; LSI Medience, Tokyo, Japan). These assays were conducted in
accordance with the manufacturer’s instructions.
PHLF was diagnosed according to the ISGLS definition (10).
The above-stated perioperative variables were compared between
patients with ISGLS grade B/C PHLF (LF group) and those
without LF. 
Statistical analyses. Statistical analyses were performed using the
SPSS statistical software version 22.0.0 (IBM, Armonk, NY, USA).
Categorical variables were compared using the chi-squared test.
Continuous variables are expressed as the mean±standard deviation,
and differences were assessed by the Mann-Whitney U-test.
Correlation coefficients were calculated with Spearman’s rank
correlation test when necessary. To determine the influence of
different variables on the outcome, a logistic regression analysis was
performed. p-Values of less than 0.05 were considered statistically
significant. To identify the most predictive combination among
promising preoperative and POD1 markers, a receiver operating
characteristic (ROC) analysis was performed using bivariate logistic
regression.
Results 
Incidence of PHLF. PHLF was diagnosed in 10 (14.7%)
patients (Table I): Grade A in one (1.5%); grade B in five
(7.4%); and grade C in four (5.9%). Thus, the 68 patients
were divided into clinically relevant LF (n=9) and non-LF
(n=59) groups. 
Clinical characteristics. The results of a comparison between
the LF and non-LF groups are shown in Table I. Preoperatively,
the LF group had poor nutritional status, as indicated by low
serum albumin, and prolonged coagulation, as indicated by
high PT-INR. The application of preoperative interventions,
such as chemotherapy, PVE, or biliary drainage, did not differ
markedly between the groups. The resection rate was higher
(p=0.054), and functional liver remnant based on the computed
tomographic volumetry was marginally lower (p=0.054) in the
LF group. In the LF group, the Hyogo University predictive
score (8) was higher and the rICGK (9) was significantly lower
than in the non-LF group. Concomitant vascular resection and
reconstruction was significantly more common in the LF group
than in the non-LF group. The operative time and amount of
bleeding did not differ markedly between the groups. The
volume of intraoperative transfusion of red-blood cell
concentrate (RCC) was significantly larger in the LF group
than in the non-LF group. The LF group showed significantly
more frequent morbidity, defined as postoperative
complications with a Dindo-Clavien classification of grade 3
or worse (27), and mortality than the non-LF group. Grade B/C
PHLF led to mortality in three of nine (33%) patients. One
Arisaka et al: Predictive Value of PT-INR and MCP1 for PHLF
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Figure 1. Changes in the inflammatory markers in the groups with (triangles) and without (circles) post-hepatectomy liver failure. The values are
expressed as the mean±standard deviation. WBC: White blood cell count; CRP: C-reactive protein; IL1β: interleukin 1β; CCL2: C-C motif
chemokine ligand 2; IL6: interleukin 6; POD: postoperative day; Pre: pre-operative. *Significantly different at p<0.05.
patient with grade C PHLF died of severe infection following
PHLF. One patient with grade B PHLF died of sepsis due to
liver abscess. Another patient with grade B PHLF died of
massive intraperitoneal bleeding.
Inflammatory markers. The preoperative inflammatory markers
were quantitatively similar for the two groups (Figure 1).
However, the levels of CCL2, IL6, and IL10 on POD1 were
significantly higher in the LF group than in the non-LF group.
In the LF group, the IL6 and IL10 levels peaked at POD1, and
the CCL2 level peaked at POD3. No marked difference in the
level of these markers was observed on POD5, except for IL6,
which was still significantly higher at POD5 in the LF group
than in the non-LF group. The white blood cell count and
IL1β level did not differ markedly between the groups at any
time points.
Coagulation and fibrinolytic factors. The preoperative
platelet count and ADAMTS13 activity were significantly
lower and the PT-INR significantly higher in the LF group
than in the non-LF group (Figure 2). Although no differences
were observed at POD1, the differences reached significance
again on POD3 and thereafter. Furthermore, the FDP-E on
POD3 and 5 and vWF activity on POD5 were higher in the
LF group than in the non-LF group, although these factors
did not differ significantly between the groups until POD1.
Construction of predictive models. ROC analyses were
performed for variables that showed significant differences
between the two groups in order to determine the cut-off
value for discriminating between the groups (Table II). The
following variables were therefore selected as the strongest
indicators of grade B/C PHLF among the pre-, intra-, and
immediately postoperative variables: rICGK, volume of RCC
during surgery, and total bilirubin (T-Bil) on POD1. The
preoperative platelet count and T-Bil on POD1 had high
specificity, while the rICGK, RCC volume, CCL2 and T-Bil
values on POD1 had the highest sensitivity (88.9%).
To further improve the sensitivity and specificity,
combination analyses were performed using bivariate logistic
regression, with bivariate combination considered
statistically valid based on the sample size and the incidence
of PHLF. Combinations correlating significantly with each
other were excluded. Combinations that were not
independent of each other were also excluded. The Youden
index of each combination is shown in Table III. The
combination of preoperative PT-INR and CCL2 on POD1
gave the largest Youden index (0.898), indicating that this
combination had the strongest ability to predict grade B/C
PHLF at POD1.
Figure 3 shows the cut-off value calculated by the Youden
index, which is illustrated by the red line. The formula for
the cut-off line for predicting grade B/C PHLF was as
follows: (Preoperative PT-INR)+(0.00079×CCL2 on
POD1)=1.37. Nine out of 15 patients (60%) above this line
developed PHLF. This predictive model had a sensitivity of
100%, specificity of 90%, positive predictive value of 60%,
and negative predictive value of 100%.
in vivo 34: 1255-1263 (2020)
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Figure 2. Changes in coagulation and fibrinolytic factors in the groups with (triangles) and without (circles) post-hepatectomy liver failure. The
values are expressed as the mean±standard deviation. PT-INR: Prothrombin time-international normalized ratio; FDP-E: fibrin and fibrinogen
degradation products-E; ADAMTS13: a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; vWF: von Willebrand factor;
Pre: pre-operative; POD: postoperative day. *Significantly different at p<0.05.
Discussion 
The present study showed that the incidence of grade B/C
PHLF was significantly associated with reduced platelet
count and ADAMTS13 activity and increased PT-INR in the
preoperative period, and with increased CCL2 and IL6 levels
on POD1. These findings corroborated the notion that
preoperative increased coagulation and postoperative
excessive inflammation were significantly associated with
the development of PHLF. Furthermore, the present study
demonstrated that the predictive model combining the
preoperative PT-INR value and the CCL2 value at POD1 had
the strongest ability to predict PHLF, suggesting that the
combination of several markers indicative of the coagulation
status and immediate inflammatory response may be useful
for predicting PHLF earlier and more precisely than existing
models.
In addition to the existing models using preoperative
variables alone (6-9), numerous preoperative indicators have
been reported as promising for predicting or preventing PHLF
(28-32). Furthermore, intraoperative factors, such as the need
for blood transfusion during surgery (30), have been reported
Arisaka et al: Predictive Value of PT-INR and MCP1 for PHLF
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Table II. A receiver operating characteristics analysis of the preoperative and postoperative day 1 variables.
Variable AUC Cut-off value 95% CI Sensitivity Specificity
Preoperative Predictive score 42.65 0.762 0.617-0.908 77.8% 65.5%
rICGK 0.06 0.880 0.759-1.000 88.9% 86.4%
Serum albumin, g/dl 2.85 0.725 0.536-0.914 55.6% 89.8%
Platelet count, 104/μl 12.25 0.755 0.576-0.935 55.6% 93.2%
PT-INR 1.135 0.770 0.555-0.986 77.8% 78.0%
ADAMTS13 activity, % 94 0.727 0.559-0.895 77.8% 62.7%
Intra-operative RCC transfusion, ml 140 0.845 0.711-0.997 88.9% 71.2%
POD1 IL6, pg/ml 106.5 0.791 0.562-1.000 77.8% 91.5%
CCL2, pg/ml 241.5 0.805 0.650-0.960 88.9% 59.3%
AST, IU/l 438 0.712 0.487-0.937 66.7% 76.3%
T-Bil, mg/dl 2.95 0.929 0.853-1.000 88.9% 94.9%
AUC: Area under the receiver operating characteristics curve; CI: confidence intervaI; rICGK: indocyanine green kinetics value for the liver remnant
[=ICG K (ICG plasma disappearance rate)×remnant liver rate]; PT-INR: prothrombin time-international normalized ratio; ADAMTS13: a disintegrin-
like and metalloproteinase with thrombospondin type 1 motifs 13; RCC: red-blood cell concentrate; IL6: interleukin 6; CCL2: C-C motif chemokine
ligand 2; AST: aspartate aminotransferase; T-bil: total bilirubin. Predictive score [=−84.6+0.933×resection rate+1.11×ICGR15+0.999×age] (8).
Table III. A receiver operating characteristics analysis using a bivariate logistic regression analysis of all combination with preoperative and
markers on postoperative day 1 (POD1). 
Preoperative Intra-operative POD1
rICGK Alb Plt PT-INR ADAMTS13 RBC IL6 CCL2 AST T-Bil
Preoperative Predictive score a b 0.655 0.741 c 0.709 c 0.571 0.475 c
rICGK c 0.780 0.71 0.736 0.744 c 0.744 0.71 0.838
Alb 0.686 c c c c 0.616 0.616 c
Plt 0.72 0.601 0.71 0.838 0.761 0.635 0.864
PT-INR 0.744 0.797 b 0.898 0.821 b
ADAMTS13 0.659 c 0.633 0.505 c
Intraoperative RCC transfusion b a c b
POD1 IL6 b 0.744 b
CCL2 c 0.753
AST 0.821
rICGK: Indocyanine green kinetics value for the liver remnant [=ICG K (ICG plasma disappearance rate)×remnant liver rate]; Alb: albumin; Plt:
platelet count; PT-INR: prothrombin time-international normalized ratio; ADAMTS13: a disintegrin-like and metalloproteinase with thrombospondin
type 1 motifs 13; RCC: red-blood cell concentrate; IL6: interleukin 6; CCL2: C-C motif chemokine ligand 2; AST: aspartate aminotransferase; 
T-Bil: total bilirubin. Predictive score [=−84.6+0.933×resection rate+1.11×ICGR15+0.999×age] (8); The values represent the Youden index of each
combination. aCombinations that had strong correlations with each other (r>0.8). bCombinations that had medium correlations with each other
(r>0.4). cCombinations that were not independent of each other according to a bivariate logistic regression analysis (p>0.1).
to be significantly associated with PHLF. In addition,
immediate postoperative factors have been considered to affect
the incidence of PHLF significantly (4, 5, 14, 23, 33, 34).
Based on these findings, PHLF is considered to be brought
about by underlying conditions as well as other factors (i.e.
pre-, intra-, and immediate postoperative variables).
In brief, the etiology of PHLF is considered multifactorial
as well as multiphasic. However, existing models have not
included variables at different time phases. We therefore
attempted to combine time-phasically different variables to
predict PHLF more precisely than the existing models.
Although our most promising model, the combination of
preoperative PT-INR and CCL2 on POD1, did not include
any intraoperative variable, the amount of RCC transfusion
during surgery, which was significantly associated with grade
B/C PHLF in the present study, was significantly correlated
with the CCL2 level on POD1. Thus, the intraoperative
events were considered to be reflected in our model.
Furthermore, several other combinations, such as the
preoperative platelet count and IL6 on POD1, preoperative
platelet count and T-bil on POD1, and rICGK and T-bil on
POD1, yielded a high Youden index almost equal to that of
the most predictive model. These findings support the
reasonableness of our idea of combining variables from
different time phases.
CCL2 is a chemokine produced by and endothelial cells
that promotes the migration of monocytes/macrophages (35).
The increased expression of CCL2 was reported to correlate
with postoperative complications and organ dysfunction
following hepatectomy (36, 37). Furthermore, liver
expression of CCL2 was reported to promote fibrosis and to
be significantly correlated with either accompanying
neutrophil infiltration or disease severity in a model of
nonalcoholic steatohepatitis (38-40). In other words, CCL2
strongly affects liver injury and regeneration by its ability to
induce the infiltration of neutrophils into the liver
parenchyma as well as to promote fibrosis. Thus, controlling
the CCL2 expression or excessive accumulation of
polymorph nuclear leukocytes in the liver may help resolve
PHLF.
Although only bivariate combinations were attempted in
the present study due to the sample size and the rate of
PHLF occurrence, the present study results suggested the
promise of several other markers. ADAMTS13 is a specific
cleaving protease for vWF. Reduced activity of ADAMTS13
has been shown in patients with liver schirrous (41) and
acute LF (42). In fact, reduced ADAMTS13 activity in the
preoperative period was significantly associated with PHLF
in the present study. In addition, IL6 is well known to be
correlated with liver injury/regeneration after hepatectomy
(43). Indeed, an increased serum IL6 level was significantly
associated with PHLF in the present study. Therefore, we are
currently constructing a prospective database to enable the
combination of three or more variables.
Although some substances, such as prostaglandin E1 (44),
have been reported to be effective for treating PHLF,
established treatments for PHLF itself have not yet been
reported. However, we feel that the earlier identification of
PHLF is very important and useful for several reasons. As
stated above, the development of PHLF is considered to be
multifactorial as well as multiphasic. Thus, earlier
intervention based on the risk stratification for PHLF before
a definitive diagnosis of PHLF is obtained may help improve
the survival outcomes of hepatectomy. Furthermore, the
meticulous correction of trivial changes that are usually
overlooked in daily practice may be of significant aid in
preventing PHLF in high-risk patients. As such, our attempt
to diagnose PHLF much earlier than POD5 seems quite
useful in terms of the availability of earlier intervention and
risk stratification for PHLF.
This study had several limitations. Firstly, the sample size
was very small. Furthermore, the present study cohort was
heterogenous in terms of the indications for hepatectomy,
background liver status, and preoperative treatments, such as
biliary drainage, PVE, anticoagulation for thrombotic
diseases, and various pre-hepatectomy chemotherapy used.
Ideally, the influence of these variables should be assessed
individually; however, the small sample size did not allow
in vivo 34: 1255-1263 (2020)
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Figure 3. The combination of preoperative prothrombin timeInternational
Normalized Ratio (PT-INR) and C-C motif chemokine ligand 2 (CCL2)
on postoperative day 1 in the groups with (triangles) and without
(circles) post-hepatectomy liver failure. The straight line represents the
formula for predicting grade B/C post-hepatectomy liver failure. Nine
out of 15 patients (60%) above this line developed post-hepatectomy
liver failure.
for such an investigation. Secondly, the inflammatory
markers and coagulation factors were assessed only in serum
in the present study. The changes in the expression of these
markers in the liver itself should have also been assessed.
However, serial liver sample extraction seemed not only
impractical but also quite invasive and risky. We therefore
abandoned it. Thirdly, it was only possible to examine
bivariate combinations in the present study. As stated above,
the combination of three or more variables may enable a
more accurate prediction than our most promising model. 
However, despite these limitations, our predictive model
has higher sensitivity and specificity than previous ones,
which supports the validity of our idea to construct models
using variables in different time phases. 
In conclusion, the combination analyses of preoperative
coagulation factor and immediate postoperative inflammatory
cytokines seems effective for predicting PHLF earlier and
more precisely than existing models. We feel that our concept
of combining multiphasic variables in order to predict PHLF
earlier and more precisely than the existing models is valuable.
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